Clinical Research Directory
Browse clinical research sites, groups, and studies.
Halova Vaginal Ovules Versus Vaginal Estriol for Genitourinary Symptoms in Postmenopausal Women
Sponsor: Perfect Care Distribution
Summary
The goal of this clinical study was to compare Halova vaginal ovules, a non-hormonal medical device, with vaginal estriol 0.5 mg, an estrogen treatment, for genitourinary symptoms in postmenopausal women. The main questions were: * How do the treatments compare in reducing bothersome symptoms and improving vaginal health? * How do the treatments affect sexual function? * What medical problems and changes in the thickness of the lining of the uterus occur during the study? * Are improvements maintained after treatment has ended? Women willing to receive either treatment were randomly assigned to Halova or estriol in a 1:1 ratio. Women who declined hormonal therapy received Halova without randomization. Participants knew which treatment they received, while the clinicians assessing clinical outcomes did not know their treatment assignment. Participants: * Used one vaginal ovule daily for the first two weeks, then one ovule twice weekly until the end of the 12-week treatment period. * Attended assessments at baseline, Week 12, and Week 24 for symptoms, vaginal health, sexual function, safety, and the thickness of the lining of the uterus. * Received telephone monitoring at Weeks 2, 4, and 8 for treatment use, tolerability, medical problems, and satisfaction. * Received individualized menopause-related education and written materials, and completed a questionnaire about knowledge, attitudes, and behaviors at baseline and Week 12.
Official title: Comparison of the Efficacy and Safety of Halova With Vaginal Estriol Therapy in the Management of Genitourinary Symptoms in Postmenopausal Women
Key Details
Gender
FEMALE
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
252
Start Date
2025-03-07
Completion Date
2026-06-22
Last Updated
2026-11-19
Healthy Volunteers
No
Interventions
Halova vaginal ovules
Halova is a vaginal medical device formulated as ovules containing sodium hyaluronate (5 mg per ovule) and xylitol (3 mg per ovule), together with semi-synthetic glycerides, lanolin, Aloe vera oil extract, Calendula officinalis extract, colloidal silicon dioxide, and vitamin E. One ovule was administered intravaginally daily for the first two weeks, followed by one ovule twice weekly until the end of the 12-week treatment period.
Estriol 0.5 mg vaginal ovules
Each Ovestin vaginal ovule contained estriol 0.5 mg. One ovule was administered intravaginally daily for the first two weeks, followed by one ovule twice weekly until the end of the 12-week treatment period.
Menopause-related education and counseling
All participants received individualized counseling and written educational materials about menopause, genitourinary symptoms, and available management options. A study-specific questionnaire was administered before the educational intervention at baseline and again at Week 12. This intervention was common to all three allocation arms.
Locations (1)
Arad County Clinical Emergency Hospital - Department of Obstetrics and Gynecology
Arad, Romania